Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Five Topics That Shaped Japan Pharma In 2019

Strategic Corporate Moves Dominate

Jan 07 2020

• By Ian Haydock

Scrip Perspectives 2019 to 2020 — Corporate Moves Dominate Japan Developments

Related Content

New Japan PMDA Head Brings Strong Clinical, Patient Focus To Role

Jun 21 2019

EFPIA Wants Continued And More Inclusive Japan Policy Dialog

Sep 27 2019

Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T

Mar 29 2019

Takeda Sheds Products, Employees To Stada In $660m Move

Nov 05 2019

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Nov 06 2019

Dainippon’s Lead Boston Asset Hits Wall In Pancreatic Cancer

Jul 04 2019

Cell Therapies Forge Ahead In Japan with Reimbursement, Approval Decisions

Feb 22 2019

Astellas Strengthens Next-Gen I-O Hand With $665m Xyphos Buy

Dec 27 2019

Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance

Dec 16 2019

Astellas To Pay $3bn For Gene Therapy Company Audentes

Dec 03 2019

Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset

Mar 29 2019

Related Companies

Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

Daiichi Sankyo Co., Ltd.

Sumitomo Pharma Co., Ltd.

STADA Arzneimittel AG

AstraZeneca PLC

Roivant Sciences Ltd.

SanBio Co., Ltd

Astellas Pharma, Inc.

Astellas Gene Therapies

Novartis AG

AbbVie Inc.

Eisai Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

Shionogi & Co. Ltd.

Additional Topics

Japan Asia Pacific Business Strategies Commercial M & A Cancer BioPharmaceutical

More from Japan

More from Focus On Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window